HDA will be carrying forward the early lessons learned from COVID-19 pandemic and supporting response efforts in 2021, writes President and CEO Chip Davis in the January 4 issue of Chain Drug Review — particularly as distributors play a role in the largest public vaccination effort in recent memory. Davis provided his perspective on the year ahead, along with other healthcare trade association leaders, as part of the publication’s 2021 “Pharmacy Outlook” feature.
Since the emergence of COVID-19, HDA distributor members have worked tirelessly to navigate the exceptional and unprecedented demands of this public health emergency. From managing unique inventory demands of the first hotspots, to ensuring access to emerging treatment options and testing, HDA members draw upon their extensive supply and distribution networks, logistics expertise and experience navigating public health emergencies. Moreover, distributors are committed to the public- and private-sector partnerships that are critical in combating COVID-19, fueling our recovery and improving pandemic resiliency for the future.
On October 27, HDA and The Hill brought together policymakers, leaders in the pharmaceutical industry and public health experts to discuss the supply chain’s response during COVID-19. In conversation with Steve Clemons, Editor-in-Chief of The Hill, speakers provided key insights on ensuring the strength and resilience of the pharmaceutical supply chain during this unprecedented crisis. Below are five takeaways from the dialogue.
The emergence of COVID-19 marked the beginning of a public health crisis the scale of which we have never seen. Amid this unprecedented challenge, the pharmaceutical supply chain — powered by distributors — quickly adapted and adjusted to the global pandemic, protecting the steady supply of critical, lifesaving medicines to hospitals, pharmacies, providers and patients.
The successful development of COVID-19 vaccines will mark a groundbreaking step in our fight against the pandemic. However, the massive demand for approved vaccines and therapies as they come to market will require extensive coordination across the pharmaceutical supply chain and with the public sector.